Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it has entered into a licensing agreement with Novartis for Marina Biotech's Conformationally Restricted Nucleotide technology for the development of both single- and double-stranded oligonucleotide therapeutics. 

Pryor Cashman Partners Larry Remmel and Steve Goodman and Counsel Michael Campoli represented Marina Biotech in the transaction.